Figure 3.
Figure 3. Kaplan-Meier estimated 2-year DFS and OS of 31 patients who underwent high-dose 90Y-ibritumomab tiuxetan and ASCT in NHL.

Kaplan-Meier estimated 2-year DFS and OS of 31 patients who underwent high-dose 90Y-ibritumomab tiuxetan and ASCT in NHL.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal